CAR T-Cell Therapy Results in Secondary Primary Cancers in Approximately 4% of Patients
Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.
Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.
Atezolizumab and bevacizumab yielded a median OS of 14.0 months vs 14.6 months with tremelimumab followed by durvalumab, a retrospective cohort study found.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Past recipients of this award are listed on this page.
Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related cardiac events than those treated with other EGFR tyrosine kinase inhibitors.“Despite…
The EMA’s CHMP has adopted a positive opinion regarding frontline nivolumab plus ipilimumab in unresectable or advanced hepatocellular carcinoma.
Discover emerging themes and early-stage clinical oncology pipelines at the second AACR Oncology Industry Partnership event.
An abstract is unavailable.
5 articles suggested by Wafik El-Deiry / Adrià Bernat, Alexander J Lazar, Angie Chen, Arola Fortian, Biyuan Wang, Boqiang Lyu, cancer, Chia-Kuei Mo, Collin
The Annual Meeting program will deliver the top science and education related to the field of radiation oncology.
Annals of Surgical Oncology – Neoadjuvant chemotherapy followed by surgery (NAC-S) is the standard therapy for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan.…